## DEVELOPMENT CORP.

THE OWNER WHEN

## TSXV: ELC FRA: QLDN

www.elyseedevelopment.com

May 2025

Cactus Mine Project Casa Grande, AZ

#### **DEVELOPMENT CORP.**

#### FORWARD LOOKING STATEMENT

This presentation is not a prospectus, offering memorandum, or advertisement or a public offering of securities. This presentation is for information purposes only and does not constitute an offer to sell or a solicitation to buy the securities described herein but is solely for purposes of providing information regarding Elysee Development Corp. ("Elysee Development"). No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon this Presentation, and any representation to the contrary is an offence. The information contained in this presentation does not purport to be all-inclusive or to contain all information that readers may require. Readers are encouraged to conduct their own analysis and reviews of Elysee Development and of the information contained in this presentation.

This presentation is for the confidential use of only those persons to whom it is provided. By their acceptance of this presentation, recipients agree that they will not transmit, reproduce or make available to any other person this presentation or any of the information contained herein.

Certain information included in this presentation, including any information as to future financial or operating performance and other statements that express expectations or estimates of future performance, constitute "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements are not guarantees of future performance. Readers are cautioned that while Elysee Development has paid dividends in the past, there is no guarantee that it will pay dividends in the future. The payment of dividends is at the discretion of the board and is subject to the availability of cash, among other factors. Similarly, while Elysee Development has historically had increases in its earning per share and net asset value, there is no guarantee that it will continue to do so – past performance is not indicative of future performance. Elysee Development's performance is subject to numerous risks and uncertainties. Readers are encouraged to review and consider the risk factors set out in Elysee Development's management discussion and analysis available at <u>www.sedar.com</u>. Elysee Development disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements.

#### **NON-IFRS MEASURES**

Elysee Development discloses in this Presentation a number of financial measures that are presented using methodologies other than IFRS, including earnings per share ("EPS"), dividend yield and net asset value ("NAV"). Elysee Development uses these measures in managing its business, including performance measurement, and believes it is helpful to readers to supplement their overall understanding of Elysee Development's business. These measures should not be considered a substitute for similar financial measures calculated in accordance with IFRS. Elysee Development cautions that these non-IFRS measures may differ materially from calculations disclosed by other business.

**DEVELOPMENT CORP.** 

## WHO WE ARE

A diversified investment company with a focus on mining and exploration. Gold, silver, copper & energy metals

>>> Access to significant deal flow not open to all investors. Investments include private placements, convertible debentures and private equity A track record of success in creating significant shareholder value.

Returning capital to shareholders. Dividend payments & share buybacks.


>>>> High level of insider ownership.

## **A TRACK RECORD OF**



**Profitability & Dividend Growth** 

**DEVELOPMENT CORP.** 



Dividends Earnings

## Paid a total of \$0.28 per share in dividends since 2013

## **ELYSEE** Shareholder Value ■ NAV Dividend Payment **DEVELOPMENT CORP.** \$0.80 \$0.70 \$0.60 \$0.50 \$0.40 \$0.30 \$0.20 \$0.10 \$-

Dec 31 2019

Dec 31 2020

Dec 31 2021

Dec 31 2022

Dec 31 2023

Nov 30 2013

Nov 30 2014

Nov 30 2015

Nov 30 2016

Nov 30 2017

Nov 30 2018


5

Mar 31 2025

Dec 31 2024

#### **DEVELOPMENT CORP.**

## ALLOCATION of Investments




## Portfolio as of March 31, 2025

Cash and Equivalents	\$1.9 Million
Equities	\$12.1 Million
Warrants	\$0.4 Million
Convertible Bonds	\$1.4 Million
	\$15.8 Million

Net Asset Value (NAV) per Share: \$0.49

## Equity & Convertible Investments by Sector

(as of March 31, 2025)



**ELYSEE** 


**DEVELOPMENT CORP.** 

## TOP 5 EQUITY INVESTMENTS



#### **DEVELOPMENT CORP.**

## 1 **VUS VANADIUM** LLC.



23

36.

## PRIVATE EQUITY INVESTMENTS



**DEVELOPMENT CORP.** 



**US Vanadium LLC.** processes industrial waste material into the highest-purity Vanadium Pentoxide (V2O5) in the world as well as Ultra-High Purity Electrolyte for Vanadium Redox Flow Batteries. **BioAegis** is a clinical stage company on developing Gelsolin, an immune regulatory protein for treating acute and chronic inflammatory diseases, with a current focus on Acute Respiratory Distress Syndrome (ARDS), a life-threatening lung condition.



www.bioaegistherapeutics.com

**BioAegis Therapeutics** expects to **unlock the healing powers of gelsolin** and continue to develop new treatments for disease.

**Plasma Gelsolin ("pGSN")** is a master regulator of the immune system. It is a unique anti-inflammatory without immunosuppressive properties.

**Phase 2 clinical trials** for the treatment of ARDS are currently underway in 13 countries, including Canada, the USA and a number of EU countries.

ELYSEE

**DEVELOPMENT CORP.** 

**Recent non-dilutive funding:** 

- grant from BARDA\* of US\$20 million for continuing research on ADRS
- grant of US\$3 Million from the U.S. Navy for research on use for treatment of decompression sickness for divers.

\* Biomedical Advanced Research and Development Authority is a component of the U.S. Department of Health and Human Services

355.90

23.05

# **VUS**VANADIUM

www.usvanadium.com

Private equity investment of US\$2.1 Million.



Expanding production of high purity vanadium products in two integrated processing facilities in Arkansas, USA

A global leader in high-purity V2O5 and ultra-high-purity Vanadium electrolyte for Vanadium Redox Flow Battery (VRFB).

### **Recent announcements of:**

- Strong support from US Government for domestic buildout of grid-level Vanadium Redox Flow Battery infrastructure.
- Long term offtake agreement for electrolyte with Austrian-based CellCube Energy Storage GmbH, a leader in VRFB batteries for industrial applications and large-scale grid systems.



DEVELOPMENT CORP.

Martin Burian CPA, CA

Guido Cloetens

#### **CHAIRMAN & DIRECTOR**

- 30+ years of experience in finance & investment banking, is an independent member of the board of several public companies & holds the designation ICD.D from the Institute of Corporate Directors.
- He is currently Managing Director, Investment Banking at RCI Capital Group

#### **PRESIDENT & CEO**

- Certified investment advisor (EHSAL Brussels) with a degree in Corporate Finance, Investment and financial statement analysis (ULB)
- Director of several public and private companies.
- Over 31 years of experience in wealth management and institutional investing

# EXPERIENCED MANAGEMENT

Gaston Reymenants

#### DIRECTOR

- Graduated from the Universities of Brussels, Leuven & Antwerp in Economics, Industrial Marketing, International Law, and Foreign Languages
- 20+ years with Falconbridge International in various managerial positions & was part of the joint venture with Norilsk Kombinat. Serves as a director of Global Energy Metals and Greenbridge Resources Ltd.

### Thibaut Lepouttre

#### DIRECTOR

- Has been researching & analyzing mining companies since 2008 when he founded Caesars Report, the 1<sup>st</sup> English mining website in Continental Europe
- Has a Bachelor of Law degree from the University of Leuven, Belgium and 2 master degrees in economics
- 16+ years in the mining sector & has served as a Technical Advisor to Elysee since May 2022



## **DEVELOPMENT CORP.**



Shares Issued:	28,291,613 shares
Options:	1,850,000 options
Restricted Share Units:	140,000 RSUs
Warrants:	(none)
Fully-Diluted:	30,281,613 shares

**DEVELOPMENT CORP.** 

## Increased M&A Activity in the mining sector





## **DEVELOPMENT CORP.**

Cactus Mine Project Casa Grande, AZ

# **CONTACT US**

Guido Cloetens, President & CEO info@elyseedevelopment.com ↑1 (778) 373-1562 www.elyseedevelopment.com